Rheumatoid Arthritis Flashcards
diagnosis of rheumatoid arthritis
at least 4 of these: morning stiffness for >1hr, arthritis of >=3 joints for >6wks, arthritis of hand joints, symmetric arthritis for >6wks, rheumatoid nodules, serum rh factor positive, radiographic changes typical of RA; FOGGY to diagnose
treatment modalities for rheumatoid arthritis
rest, motion exercise, physiotherapy, diet, heat, cold; symptomatic tx w/nsaid; dz modifying drugs (dmard); immunosuppressant drugs (w/fair up); corticosteroids, surgery, novel/experimental
arichidonic acid pathway
http://o.quizlet.com/5bUb3BmmAwqT3O4S76h2Vg.png
NSAIDs clinical effects in rheumatoid arthritis
anti-inflammatory; analgesic
risk for NSAID-induced GI bleeding
low: acetaminophen (not used in RA), ibuprofen; intermediate: aspirin, diclofenac, diflunisal; high: piroxicam, indomethacin, ketoprofen
clinical effects of the arichidonic acid pathway
http://o.quizlet.com/91-u88uHatI7uxBV7RGEkQ.png
disease modifying anti-rheumatic drugs (DMARDs) uses
to reduce/prevent joint damage (nsaids relieve symptoms, no real effect on destruction)
DMARDs features
poorly understood mech’s; none effective in >60% pt’s -> unpredictable efficacy; therapeutic effects take 2-4 mths; if ineffective in pt once, not considered in future for same pt
important DMARDs
methotrexate (MTX), gold compounds, cytotoxic agents
methotrexate characteristics
aminopterin analogue; cytostatic drug
methotrexate pk
oral, subQ, im, iv
methotrexate pd in rheumatoid arthritis
low doses DMARD -> module immune system; inhibit AICAR transformylase, thymidilate synthetase pathway (higher conc) -> dec PMN chemotaxis; inhibit DHFR -> dec lymphocyte, macrophage gxn
methotrexate moa1
-> inc AICAR -> AICAR inhibits ADA, AMP deaminase -> AMP, adenosine inc, AMP -> adenosine -> inc inc adenosine -> act on A2b receptors -> suppress NF-kappaB activation induced by TNF, other inflammatory mediators
methotrexate moa2
http://o.quizlet.com/6qxx-VwnznZgu.kP5hMW6g.png
methotrexate interactions
nsaid reduce Cl; combo w/sulfonamides potentiates bone marrow toxicity